Products Affected - Description

• • Moxifloxacin injection, Fresenius Kabi, 400 mg/250 mL, premixed bag, 12 count, NDC 63323-0850-74 - discontinued
  • Moxifloxacin injection, Mylan Institutional (Viatris), 400 mg/250 mL, premixed bag, 12 count, NDC 67457-0323-25

Reason for the Shortage

• • Fresenius Kabi recently discontinued moxifloxacin injection.
  • Viatris did not provide a reason for the shortage. They are sole suppliers of moxifloxacin injection.

Available Products

• • There are no presentations available

• • Viatris has moxifloxacin 400 mg/250 mL premixed bags on back order and the company estimates a release date of mid- to late-November 2026.

• • Indicated in adult patients for the treatment of community acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, complicated intraabdominal infections, and uncomplicated skin and skin structure infections.[1]
  • Off-label indications: sexually transmitted infections, tuberculosis, surgical prophylaxis, and neutropenic fever.[1]

• • 1. Could cause tendinitis and tendon rupture. 2. Potential for causing peripheral neuropathy. 3. Exacerbation of Myasthenia Gravis. 4. QT prolongation risk.

• • Community acquired pneumonia:[2] 1. First line: amoxicillin 1 g three times daily. 2. Second line: doxycycline 100 mg twice daily. 3. Third line: azithromycin 500 mg on first day then 250 mg daily. 4. Fourth line: moxifloxacin 400 mg once daily, reserved for patients with B-lactam allergy or comorbidities or recent antibiotic exposure. Could also use levofloxacin 750 mg daily for patients with comorbidities/inpatient monotherapy.
  • Acute bacterial sinusitis:[3] 1. First line: amoxicillin with clavulanate 875/125 mg for 5-10 days OR doxycycline 100 mg twice daily for 10 days. 2. Second line: moxifloxacin 400 mg once daily, reserved for patients with B-lactam allergy, severe infection, or failure of first line therapy. Could also use levofloxacin 500-750 mg daily for patients with B-lactam allergy.
  • Acute bacterial exacerbation of chronic bronchitis: (Severe exacerbation) [4] 1. First line: amoxicillin/clavulanate 875/125 mg twice daily. 2. Second line: levofloxacin 750 mg daily. 3. Third line: moxifloxacin 400 mg once daily, reserved if failure of first/second line or allergy/intolerance to them or comorbidities.
  • Complicated intraabdominal infections:[5] 1. First line: cefoxitin 2 grams IV every 6 hours. 2. Second line: ertapenem 1 gram IV every 24 hours. 3. Not usually recommended unless B-lactams are contraindicated or mild-moderate severity, moxifloxacin 400 mg once daily. Could also use ciprofloxacin 400 mg IV every 8-12 hours combined with metronidazole for B-lactam allergy.
  • Skin and skin structure infections: dependent on lab results, moxifloxacin is not the first line agent.

• 1. Moxifloxacin. Lexicomp Online. Wolters Kluwer Clinical Drug Information. Hudson, Ohio, USA. Accessed; Accessed June 3, 2026.
  2. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of america. American Journal of Respiratory and Critical Care Medicine. 2019;200(7):e45-e67. doi:https://doi.org/10.1164/rccm.201908-1581st
  3. Chow AW, Benninger MS, Brook I, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clinical Infectious Diseases. 2012;54(8):e72-e112. doi:https://doi.org/10.1093/cid/cis370
  4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. GOLD; 2024. https://goldcopd.org/2024-gold-report/
  5. Robert A Bonomo, Anthony W Chow, Morven S Edwards, Romney Humphries, Pranita D Tamma, Fredrick M Abrahamian, Mary Bessesen, E Patchen Dellinger, Ellie Goldstein, Mary K Hayden, Keith Kaye, Brian A Potoski, Jesús Rodríguez Baño, Robert Sawyer, Marion Skalweit, David R Snydman, Sarah Pahlke, Katelyn Donnelly, Jennifer Loveless, 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Complicated Intra-abdominal Infections: Risk Assessment, Diagnostic Imaging, and Microbiological Evaluation in Adults, Children, and Pregnant People, Clinical Infectious Diseases, 2024;, ciae346, https://doi.org/10.1093/cid/ciae346